Syndax Pharmaceuticals, Inc. (SNDX) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin -165.6%, revenue growth 627.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $172.35M |
| Revenue (TTM) | $0.3B |
| Net Margin | -165.6% |
| Operating Margin (TTM) | -48.7% |
| Net Debt / EBITDA | -0.1 |
| Revenue Growth (YoY) | 627.8% |
| EPS Growth (YoY) | -11.6% |
| FCF Growth (YoY) | 17.6% |
| Price / Book | 115.38 |
| Price / Sales | 7.01 |
| Altman Z-Score | -2.20 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
SNDX overview · SNDX earnings · SNDX KPIs · SNDX documents · SNDX ownership · SNDX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.